Medico Remedies Limited
Medico Remedies Limited (MEDICO) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
medicoremediesindia.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 41 Cr | 38 Cr | 53 Cr |
| Operating expenses (approx.) | 35 Cr | 35 Cr | 50 Cr |
| EBITDA | 7 Cr | 3 Cr | 3 Cr |
| OPM % | 16.1% | 7.4% | 5.2% |
| Other income | 0.29 Cr | 0.66 Cr | 2 Cr |
| Interest | 0.49 Cr | 0.28 Cr | 0.24 Cr |
| Depreciation | 0.77 Cr | 0.77 Cr | 0.73 Cr |
| Profit before tax | 6 Cr | 2 Cr | 3 Cr |
| Tax % | 23.8% | 25.3% | 26.1% |
| Net profit | 4 Cr | 2 Cr | 3 Cr |
| EPS (₹) | ₹0.52 | ₹0.22 | ₹0.31 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 151 Cr | Sign in for TTM |
| Operating expenses (approx.) | 136 Cr | Sign in for TTM |
| EBITDA | 15 Cr | Sign in for TTM |
| OPM % | 9.9% | Sign in for TTM |
| Other income | 3 Cr | Sign in for TTM |
| Interest | 1 Cr | Sign in for TTM |
| Depreciation | 3 Cr | Sign in for TTM |
| Profit before tax | 14 Cr | Sign in for TTM |
| Tax % | 25.3% | Sign in for TTM |
| Net profit | 10 Cr | Sign in for TTM |
| EPS (₹) | ₹1.22 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 17 Cr |
| Reserves | 46 Cr |
| Borrowings | 15 Cr |
| Other liabilities | 43 Cr |
| Total liabilities | 120 Cr |
| Fixed assets (net) | 21 Cr |
| CWIP | 1 Cr |
| Investments | 2 Cr |
| Loans & advances | 0.19 Cr |
| Inventories | 27 Cr |
| Trade receivables | 57 Cr |
| Cash & bank | 1 Cr |
| Other assets | 11 Cr |
| Total assets | 120 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 5 Cr |
| Cash from investing | -3 Cr |
| Cash from financing | -0.52 Cr |
| Net cash flow | 0.91 Cr |
| Free cash flow (OCF − Capex) | 5 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 19.0% |
| ROE % | 16.2% |
| Debtor days | 138 |
| Inventory days | 87 |
| Days payable | 113 |
| Cash conversion cycle | 112 |
| Debt / equity | 0.24 |
| Current ratio | 1.70 |
| Net debt / EBITDA | 0.91 |
Compare with peers
Loading peers…